CSL Licenses Lixudebart in $355 Million Initial Deal

Company CSL; Alentis Therapeutics Event Type Licensing and co-development Modality Monoclonal antibody Asset Lixudebart (ALE.F02) Target Exposed claudin-1 Disease Area ANCA-associated vasculitis with RPGN; focal segmental glomerulosclerosis; primary sclerosing cholangitis Summary CSL and Alentis entered a global collaboration to develop and promote lixudebart, an antibody…